πŸ‡ΊπŸ‡Έ FDA
Patent

US 11266641

Formulations of a somatostatin modulator

granted A61KA61K31/4709A61K45/06

Quick answer

US patent 11266641 (Formulations of a somatostatin modulator) held by CRINETICS PHARMACEUTICALS, INC. expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRINETICS PHARMACEUTICALS, INC.
Grant date
Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/4709, A61K45/06, A61K9/0053, A61K9/1611